368 related articles for article (PubMed ID: 19298583)
41. Advances in the systemic treatment of pancreatic neuroendocrine tumors.
Yalcin S
Cancer Treat Rev; 2011 Apr; 37(2):127-32. PubMed ID: 20705397
[TBL] [Abstract][Full Text] [Related]
42. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors.
Pavel ME; Wiedenmann B
Horm Metab Res; 2011 Nov; 43(12):844-53. PubMed ID: 22105475
[TBL] [Abstract][Full Text] [Related]
43. The somatostatin receptor subtype 5 in neuroendocrine tumours.
van der Hoek J; Lamberts SW; Hofland LJ
Expert Opin Investig Drugs; 2010 Mar; 19(3):385-99. PubMed ID: 20151855
[TBL] [Abstract][Full Text] [Related]
44. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Phan AT; Kunz PL; Reidy-Lagunes DL
Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
[TBL] [Abstract][Full Text] [Related]
45. Radioguided surgery and systemic radionuclide therapy of neuroendocrine tumours.
Hodolic M; Fettich J; Marzola MC; Tonini E; Al-Nahhas A; Rubello D
In Vivo; 2010; 24(1):97-100. PubMed ID: 20133983
[TBL] [Abstract][Full Text] [Related]
46. [Expert dialogue: neuroendocrine tumours of the lungs and gastroenteropancreatic system].
Hörsch D; Sayeg Y; Bonnet R; Kaemmerer D; Presselt N; Baum RP
Pneumologie; 2012 Jan; 66(1):44-8. PubMed ID: 22250054
[TBL] [Abstract][Full Text] [Related]
47. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters.
Niederle MB; Hackl M; Kaserer K; Niederle B
Endocr Relat Cancer; 2010 Dec; 17(4):909-18. PubMed ID: 20702725
[TBL] [Abstract][Full Text] [Related]
48. Chemotherapy for gastro-enteropancreatic endocrine tumours.
O'Toole D; Hentic O; Corcos O; Ruszniewski P
Neuroendocrinology; 2004; 80 Suppl 1():79-84. PubMed ID: 15477723
[TBL] [Abstract][Full Text] [Related]
49. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
50. Biotherapies for GEP-NETs.
Öberg K
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):833-41. PubMed ID: 23582922
[TBL] [Abstract][Full Text] [Related]
51. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours.
Dimitriadis GK; Weickert MO; Randeva HS; Kaltsas G; Grossman A
Endocr Relat Cancer; 2016 Sep; 23(9):R423-36. PubMed ID: 27461388
[TBL] [Abstract][Full Text] [Related]
52. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.
Ramage JK; Davies AH; Ardill J; Bax N; Caplin M; Grossman A; Hawkins R; McNicol AM; Reed N; Sutton R; Thakker R; Aylwin S; Breen D; Britton K; Buchanan K; Corrie P; Gillams A; Lewington V; McCance D; Meeran K; Watkinson A;
Gut; 2005 Jun; 54 Suppl 4(Suppl 4):iv1-16. PubMed ID: 15888809
[No Abstract] [Full Text] [Related]
53. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
Klöppel G
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
[TBL] [Abstract][Full Text] [Related]
54. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.
Anthony LB; Woltering EA; Espenan GD; Cronin MD; Maloney TJ; McCarthy KE
Semin Nucl Med; 2002 Apr; 32(2):123-32. PubMed ID: 11965607
[TBL] [Abstract][Full Text] [Related]
55. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
[TBL] [Abstract][Full Text] [Related]
56. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors.
Halperin DM; Kulke MH; Yao JC
Annu Rev Med; 2015; 66():1-16. PubMed ID: 25341008
[TBL] [Abstract][Full Text] [Related]
57. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
Narayanan S; Kunz PL
Hematol Oncol Clin North Am; 2016 Feb; 30(1):163-77. PubMed ID: 26614375
[TBL] [Abstract][Full Text] [Related]
58. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up.
Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW
J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065
[TBL] [Abstract][Full Text] [Related]
59. Future perspectives on neuroendocrine tumors.
Castellano D; Salazar R; Raymond E
Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():35-40. PubMed ID: 21327890
[TBL] [Abstract][Full Text] [Related]
60. New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors.
Weber M
Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):12-7. PubMed ID: 25768104
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
